-
Innovation Ranking
NewInnovation Ranking – IVERIC bio Inc
IVERIC bio Inc (IVERIC bio), formerly known as Ophthotech Corp, is a biopharmaceutical company that develops novel therapeutics to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company’s products include Zimura, a complement inhibitor for stargardt disease. It provides Fovista, an anti-platelet-derived growth factor (PDGF). IVERIC bio offers gene therapy research programs, dry age-related macular degeneration and ophthalmic orphan programs. The company seeks to collaborate with companies and academic institutions to develop gene therapy product...
-
Product Insights
Retinal Degeneration – Drugs In Development, 2023
Global Markets Direct’s, ‘Retinal Degeneration - Drugs In Development, 2023’, provides an overview of the Retinal Degeneration pipeline landscape. The report provides comprehensive information on the therapeutics under development for Retinal Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Retinitis Pigmentosa (Retinitis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Retinitis Pigmentosa (Retinitis) - Drugs In Development, 2023’, provides an overview of the Retinitis Pigmentosa (Retinitis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Juvenile Macular Degeneration (Stargardt Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Juvenile Macular Degeneration (Stargardt Disease) - Drugs In Development, 2023’, provides an overview of the Juvenile Macular Degeneration (Stargardt Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Leber Congenital Amaurosis (LCA) – Drugs In Development, 2023
Global Markets Direct’s, ‘Leber Congenital Amaurosis (LCA) - Drugs In Development, 2023’, provides an overview of the Leber Congenital Amaurosis (LCA) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leber Congenital Amaurosis (LCA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Usher Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Usher Syndrome - Drugs In Development, 2023’, provides an overview of the Usher Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Usher Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewNet Present Value Model: Pfizer Inc’s Fidanacogene elaparvovec
Empower your strategies with our Net Present Value Model: Pfizer Inc's Fidanacogene elaparvovec report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TPST-1495 in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TPST-1495 in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TPST-1495 in Adenocarcinoma Of The Gastroesophageal Junction Drug Details:TPST-1495 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Avacincaptad Pegol Sodium in Juvenile Macular Degeneration (Stargardt Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Avacincaptad Pegol Sodium in Juvenile Macular Degeneration (Stargardt Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Avacincaptad Pegol Sodium in Juvenile Macular Degeneration (Stargardt...